Ministry of Industry and Information Technology: Promote the deep empowerment of artificial intelligence in the entire pharmaceutical industry chain and guide enterprises to compete in an orderly manner in accordance with laws and regulations

According to the Zhitong Finance APP, on September 11, the Ministry of Industry and Information Technology held a symposium for pharmaceutical manufacturing enterprises. Minister Li Lecheng emphasized the need to accelerate the implementation of high-quality development actions in the pharmaceutical industry, consolidate the status of enterprises as the main body of innovation, promote the deep empowerment of artificial intelligence across the entire pharmaceutical industry chain, strengthen intellectual property protection, guide enterprises to compete in an orderly manner in accordance with laws and regulations, and continuously optimize the market environment and development ecology. Industry enterprises should vigorously promote the spirit of entrepreneurship, better fulfill social responsibilities, strengthen lean production and quality management, increase investment in innovation and research and development resources, and continuously enhance the Chinese pharmaceutical brand. The original text is as follows: The Ministry of Industry and Information Technology holds a symposium for pharmaceutical manufacturing enterprises On September 11, Li Lecheng, Secretary of the Party Leadership Group and Minister of the Ministry of Industry and Information Technology, presided over a symposium for pharmaceutical manufacturing enterprises, deeply studying and implementing General Secretary Xi Jinping's important instructions on the development of the biopharmaceutical industry, focusing on promoting high-quality development in the pharmaceutical industry, and further enhancing the resilience and safety level of the industrial and supply chains by listening to relevant enterprises' introductions and suggestions. At the meeting, leaders from 10 pharmaceutical enterprises engaged in in-depth exchanges on aspects such as basic drug research and development, intelligent manufacturing, innovation product breakthroughs, artificial intelligence empowerment, and intellectual property protection, introducing the production and operation conditions of their enterprises and the difficulties faced in industry development, and providing suggestions. Li Lecheng listened carefully to the entrepreneurs' speeches, responded to the suggestions and issues raised by them one by one, and requested relevant departments and units to seriously absorb and study them, promoting solutions item by item. Li Lecheng pointed out that the Party Central Committee attaches great importance to the development of the pharmaceutical industry. General Secretary Xi Jinping emphasized the need to strengthen basic research and the construction of scientific and technological innovation capabilities, firmly grasping the lifeline of the development of the biopharmaceutical industry in our own hands. In recent years, China's pharmaceutical industry has made a series of positive progress in high-quality development, with significant improvements in industrial scale and original innovation capabilities, a continuous emergence of high-quality innovative drug products, and a sustained enhancement of the resilience of the industrial and supply chains, with fruitful results in international cooperation in the pharmaceutical field. Under the new situation, the high-quality development of the industry faces new risks and challenges. We must strengthen our confidence, maintain our determination, face difficulties head-on, and lead the high-quality development of the pharmaceutical industry to continuously achieve new results through innovative breakthroughs. Li Lecheng emphasized the need to deeply study and implement General Secretary Xi Jinping's important discourse on new-type industrialization, profoundly recognize the significant importance of promoting high-quality development in the pharmaceutical industry for safeguarding people's life and health, building a national biological safety barrier, and implementing the strategies of a strong manufacturing country and a healthy China. We must earnestly implement the decisions and deployments of the Party Central Committee and the State Council, focus on enhancing the self-controllable level of the biopharmaceutical industry chain, and continuously exert efforts on key tasks such as promoting the deep integration of technological innovation and industrial innovation in the pharmaceutical industry. We should accelerate the implementation of high-quality development actions in the pharmaceutical industry, consolidate the status of enterprises as the main body of innovation, promote the deep empowerment of artificial intelligence across the entire pharmaceutical industry chain, strengthen intellectual property protection, guide enterprises to compete in an orderly manner in accordance with laws and regulations, and continuously optimize the market environment and development ecology. Industry enterprises should vigorously promote the spirit of entrepreneurship, better fulfill social responsibilities, strengthen lean production and quality management, increase investment in innovation and research and development resources, and continuously enhance the Chinese pharmaceutical brand Officials from relevant departments and affiliated units of the Ministry attended the meeting. This article is compiled from the WeChat public account "Gongxin Weibao"; edited by Xu Wenqiang from Zhitong Finance